HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Strengthens Sunscreen Testing And Label Requirements

This article was originally published in The Rose Sheet

Executive Summary

As early as June 2012, sunscreens that fail “broad spectrum” tests or have an SPF less than 15 must warn that they have not been shown to prevent cancer or early skin aging, according to an FDA final rule.

You may also be interested in...

FDA’s Proposed Sunscreen Rule Could Bring SPFs Back Down To Earth, Deter SPF Fraud Suits

SPF claims would be capped at SPF 60+ under FDA’s proposed rule, and companies would be required to label products using the lowest SPF measured in testing and maintain test records that would be accessible to FDA during inspections. The proposal also includes new broad-spectrum requirements, among a host of other changes.

SPF Claims No More Reliable In 2018 Than Previous Years – Consumer Reports

The nonprofit publication’s 2018 sunscreen ratings and buying guide reflect its own SPF testing in which a third of sunscreens again underperformed dramatically compared with labeled SPFs. Low-scoring brands may face a new wave of false-advertising litigation, with many related suits still pending in federal and state courts.

FDA Tightlipped On Status Of ‘SPF Determination’ Study, But Issue Is A Concern

FDA’s 2016 request for contractor services to perform SPF testing on US-marketed sunscreen products has come up in litigation challenging brands’ SPF claims. The agency told Rose Sheet the issue of accurately labeled SPFs is a concern, but declined to provide further update on what it characterized as a pending matter.

Related Content

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts